Kitazato Corporation (368A): FY2025 Results Summary — Record Net Sales Led by Europe and New Media Products

This article is based on publicly available IR materials and is not a recommendation to buy or sell any specific securities.

Note: Kitazato Corporation’s fiscal year ends in March. In this article, FY2025 refers to the fiscal year ended March 31, 2026, which the company labels “FY2026” (shown as “2026.3” in its tables) in its FY2026 Earnings Results Presentation dated May 11, 2026. Labels in the text and tables below follow the company’s presentation.

Kitazato Corporation, a medical device manufacturer specialized in fertility treatment fields such as in vitro fertilization, intracytoplasmic sperm injection, and frozen-thawed embryo transfer, reported increased revenue and profit with record-high net sales. Consolidated net sales reached 10,947 million yen (+6.3% YoY, record high), operating profit was 5,858 million yen (+1.3%), and net profit attributable to owners of parent increased to 3,895 million yen (+2.8% YoY). Overseas sales rose 7.1% to 7,287 million yen, driven mainly by Europe, and the overseas sales ratio was 66.6% (+0.5pt YoY).

Consolidated Results (Full-Year Actual)

Against the company’s plan, net sales achieved 103.3% (plan: 10,602 million yen), operating profit 109.0% (plan: 5,374 million yen), and net profit attributable to owners of parent 111.3% (plan: 3,498 million yen). The cost of sales ratio rose to 34.1% (2025.3: 32.3%) and the SG&A ratio to 12.4% (2025.3: 11.6%), bringing the operating profit margin to 53.5% (2025.3: 56.1%).

Item (Million yen)	2025.3 Actual	2026.3 Actual	Change	Change Rate	2026.3 Plan	Achievement Rate
Net Sales (Consolidated)	10,302	10,947	645	6.3%	10,602	103.3%
Net Sales (Standalone)	10,127	10,708	580	5.7%	10,412	102.8%
Cost of Sales	3,327 (32.3%)	3,732 (34.1%)	405	12.2%	3,785 (35.7%)	98.6%
SG&A Expenses	1,191 (11.6%)	1,355 (12.4%)	164	13.8%	1,442 (13.6%)	94.0%
Operating Profit	5,782 (56.1%)	5,858 (53.5%)	76	1.3%	5,374 (50.7%)	109.0%
Net Profit Attributable to Owners of Parent	3,788	3,895	106	2.8%	3,498	111.3%

Ordinary profit increased by ¥135 million to ¥5,903 million (2025.3: 5,767 million yen). Gross profit contributed +¥240 million: although some cost ratios increased due to a less favorable product mix and a higher proportion of OEM products, profits increased due to production improvement effects (approximately ¥50 million) and higher sales. Negative factors were personnel expenses (△¥27 million) for recruitment to strengthen the sales and management structure, operating and certification expenses (△¥69 million), taxes and public charges / other SG&A expenses (△¥55 million) including real estate acquisition tax related to the new facility, and listing-related expenses, etc. (△¥45 million). Foreign exchange gain added +¥68 million and interest income and other non-operating income +¥25 million.

On the balance sheet, total assets were 21,996 million yen (2025.3: 19,748 million yen), including cash and deposits of 13,414 million yen (2025.3: 11,460 million yen). The FY2026 equity ratio was 93.2% (vs. 92.4% in the previous fiscal year), which the company describes as maintaining a strong equity base. The company states that investment in the new facility has been largely completed, and introduction of automation equipment is scheduled for FY2027 onward.

Sales by Region

Net sales in Japan were ¥3,660 million (+4.7% YoY), which the company attributes to strengthening marketing and sales activities and the launch of new and improved products. Overseas sales reached ¥7,287 million (+7.1% YoY). Europe grew 15.7% to 3,990 million yen on the launch of new products, and the United States rose 9.6% to 1,120 million yen, supported by stronger marketing and sales activities and market disruption caused by restructuring among competing manufacturers. China declined 22.5% to 672 million yen due to a decline in the number of patients and the emergence of low-cost domestic products. India grew 26.9% to 593 million yen, although Q4 sales decreased as planned in preparation for a distributor transition.

Region (Million yen)	2025.3 Actual	2026.3 Actual	YoY	2026.3 Plan	Achievement Rate
Net Sales	10,302	10,947	6.3%	10,602	103.3%
Japan	3,496	3,660	4.7%	3,690	99.2%
Overseas	6,805	7,287	7.1%	6,912	105.4%
Europe	3,448	3,990	15.7%	3,645	109.5%
United States	1,022	1,120	9.6%	1,179	95.0%
China	868	672	△22.5%	659	102.0%
India	467	593	26.9%	525	113.0%
Others	998	909	△8.9%	903	100.7%

Sales by Product Category

The company states that although Cryodevice was affected by temporary factors from the previous year, excluding such effects, each product category achieved steady growth. Media performed strongly due to the launch of new products, with net sales reaching ¥4,004 million (+11.0% YoY). Cryodevice recorded net sales of ¥3,081 million (-2.6% YoY), affected by changes in sales volume and pricing in China. Medical Devices remained solid both in Japan and overseas, with net sales reaching ¥2,512 million (+8.1% YoY), and Micro Tools increased mainly in Europe, with net sales reaching ¥1,099 million (+8.8% YoY).

Product Category (Million yen)	2025.3 Actual	2026.3 Actual	YoY	2026.3 Plan	Achievement Rate
Net Sales	10,302	10,947	6.3%	10,602	103.3%
Media	3,607	4,004	11.0%	3,731	107.3%
Cryodevice	3,165	3,081	△2.6%	3,131	98.4%
Medical Devices	2,324	2,512	8.1%	2,377	105.7%
Micro Tools	1,009	1,099	8.8%	1,147	95.8%
Others	194	249	28.1%	216	115.6%

By regional mix, Europe accounted for 37% of Media sales, 46% of Cryodevice sales and 56% of Micro Tools sales, while Japan accounted for 67% of Medical Devices sales. Key future initiatives listed by the company include new customer acquisition through the rollout of new cryopreservation technologies and the launch of embryo culture media (Media), sales expansion in the U.S. and Indian markets driven by egg bank market expansion and countering low-cost local imitation products in China and India through new products (Cryodevice), and expanding manufacturing sites and production capacity (Micro Tools).

FY2027 Forecast

For FY2027 (2027.3), the company plans net sales of 11,346 million yen (+3.6%), operating profit of 6,115 million yen (+4.4%) and net profit of 4,059 million yen (+4.2%). It will continue to expand its product lineup, promote certification acquisitions, and strengthen marketing and sales activities, focusing on cryopreservation-related products. The company notes that there has currently been no impact on transactions from geopolitical risks (including the Middle East situation), and such factors have not been incorporated into the forecast.

Item (Million yen)	2027.3 Plan	2026.3 Actual	YoY Change
Net Sales	11,346	10,947	3.6%
Operating Profit	6,115	5,858	4.4%
Operating Margin	53.9%	53.5%	0.4pt
Ordinary Profit	6,137	5,903	4.0%
Ordinary Margin	54.1%	53.9%	0.2pt
Net Profit	4,059	3,895	4.2%
Net Profit Margin	35.8%	35.6%	0.2pt

By region, the plan calls for Japan at 3,691 million yen (+0.8%) and overseas at 7,655 million yen (+5.0%), including Europe 4,215 million yen (+5.6%), the United States 1,205 million yen (+7.5%), China 700 million yen (+4.1%), India 593 million yen (+0.0%) and Others 941 million yen (+3.4%). The company expects Japan, Europe, and Asia to maintain stable sales growth, while sales expansion efforts will be strengthened in the United States and the Middle East; in China and India, which it positions as key strategic markets, it will launch new initiatives aimed at becoming the market leader within the next five years. By product category, the plan is Media 4,157 million yen (+3.8%), Cryodevice 3,191 million yen (+3.6%), Medical Devices 2,620 million yen (+4.3%), Micro Tools 1,122 million yen (+2.2%) and Others 253 million yen (+1.4%).

Shareholder Returns

The company aims to maintain a stable dividend with a target consolidated payout ratio of 40% or more annually. A dividend of ¥41 per share is planned for FY2026, with a consolidated dividend payout ratio of 42.1% (2026.3, proposed). Dividends per share were ¥40 for 2024.3 (payout ratio 40.3%) and ¥41 for 2025.3 (payout ratio 43.3%). Although a dividend of ¥41 per share is currently forecast for FY2027, the company states it will continue to be reviewed in light of profit growth and investment conditions.

Future Initiatives

Under its corporate philosophy “Happiness, for the Next Generations,” the company positions its initiatives as addressing social issues such as declining birthrates and population decline. Looking ahead five years, it lists business investments (expansion into egg and sperm banking and regenerative medicine, and new business development in pharmaceuticals and in vitro diagnostics), facility investments (review and optimization of manufacturing lines, establishment of research facilities) and sales investments (establishment of overseas subsidiaries, investment in overseas joint venture businesses, and building a global network of medical institutions). The company describes itself as a research and development-driven company that will continue to invest proactively in R&D to improve pregnancy success rates, while reducing manufacturing and sales costs to maintain high profitability and deliver returns to shareholders.

This article is an analysis based on publicly available information and is not a recommendation to buy or sell any specific securities. Investment decisions are your own responsibility.